View Past PerformanceOpus Genetics 대차대조표 건전성재무 건전성 기준 점검 5/6Opus Genetics 의 총 주주 지분은 $15.3M 이고 총 부채는 $1.1M, 이는 부채 대 자기자본 비율을 7.4% 로 가져옵니다. 총자산과 총부채는 각각 $50.2M 및 $34.9M 입니다.핵심 정보7.36%부채/자본 비율US$1.13m부채이자보상배율n/a현금US$45.09m자본US$15.35m총부채US$34.90m총자산US$50.24m최근 재무 건전성 업데이트Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In GrowthJul 12모든 업데이트 보기Recent updatesCEO & Director notifies of intention to sell stock Apr 24Opus Genetics, Inc. announced that it expects to receive $159.928 million in funding from Oberland Capital Management LLCApr 07High number of new directors Mar 26Consensus EPS estimates fall by 19%, revenue upgraded Mar 19CEO & Director notifies of intention to sell stock Mar 17Opus Genetics, Inc., Annual General Meeting, Apr 20, 2026Mar 14Price target increased by 7.5% to US$9.50 Mar 12Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 10Price target increased by 14% to US$8.83 Mar 02Opus Genetics, Inc. Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual MeetingFeb 27Opus Genetics, Inc. Announces Fda Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaFeb 25Opus Genetics, Inc. announced that it has received $25.000002 million in funding from Adage Capital Management, L.P., Trails Edge Capital Partners, LP, Marshall Wace LLPFeb 20Opus Genetics, Inc. announced that it expects to receive $25.000002 million in funding from Adage Capital Management, L.P., Trails Edge Capital Partners, LP, Marshall Wace LLPFeb 14Revenues Not Telling The Story For Opus Genetics, Inc. (NASDAQ:IRD) After Shares Rise 43%Feb 07New minor risk - Share price stability Jan 30Opus Genetics, Inc. Launches Gene Therapy Clinical Trial for Mertk-Related Retinitis PigmentosaJan 27Independent Chairman recently bought US$324k worth of stock Jan 02Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27%Dec 11Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best DiseaseDec 10Consensus EPS estimates fall by 16%, revenue upgraded Nov 21Third quarter 2025 earnings: EPS misses analyst expectations Nov 14Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best DiseaseNov 13Opus Genetics, Inc. Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal DiseaseNov 08Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $23 million.Nov 06Price target increased by 13% to US$6.80 Oct 09New major risk - Revenue and earnings growth Oct 06Opus Genetics, Inc. Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5Oct 02Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking After Shares Rocket 31%Sep 09Opus Genetics, Inc. Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast ConditionsSep 05Opus Genetics, Inc. Appoints Rob Gagnon as Chief Financial OfficerSep 03Opus Genetics Inherited Retinal Disease Programs Featured At Medical and Industry Conferences in SeptemberAug 28Opus Genetics, Inc. announced that it has received $3.5 million in fundingAug 26Consensus revenue estimates decrease by 18%, EPS upgraded Aug 20Opus Genetics Announces FDA Clearance of Ind Application for Gene Therapy Candidate OPGx-Best1Aug 19New major risk - Financial position Aug 14Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 14Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is LackingJul 11Opus Genetics, Inc. Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaJun 26+ 2 more updatesOpus Genetics, Inc. Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast ConditionsJun 02Consensus revenue estimates increase by 16% May 22Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest ResultsMay 19First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind May 16Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy CandidateMay 07Opus Genetics Announces One-Year Results from Adult Patients Treated in the Ongoing Phase 1/2 Study of Its Lead Gene Therapy Candidate OPGx-LCA5May 06Price target decreased by 13% to US$9.25 Apr 11Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A CatchApr 09Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal DiseasesApr 08Consensus revenue estimates increase by 34% Apr 07Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $5.2 million.Apr 05Opus Genetics, Inc., Annual General Meeting, Apr 30, 2025Apr 04Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 01New major risk - Shareholder dilution Mar 25Opus Genetics, Inc. announced that it has received $1.500001 million in fundingMar 25Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.Mar 21+ 1 more updateOpus Genetics, Inc. Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025Mar 06Opus Genetics, Inc. Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% ProgramsFeb 26Opus Genetics, Inc. Announces First Pediatric Patient Was Dosed in its Ongoing Phase 1/2 Clinical Trial Evaluating OPGx-LCA5, its Investigational Gene Therapy for the Treatment of Leber Congenital AmaurosisFeb 18New major risk - Shareholder dilution Jan 15Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $40 million.Jan 14CEO & Director recently bought US$98k worth of stock Jan 02Opus Genetics, Inc. to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024Dec 04CEO & Director recently bought US$101k worth of stock Nov 21Consensus revenue estimates increase by 40%, EPS downgraded Nov 20Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 14Price target decreased by 21% to US$13.67 Oct 23Ocuphire Pharma, Inc. (NasdaqCM:OCUP) acquired Opus Genetics, Inc. for $25.8 million.Oct 23Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in OphthalmologyOct 01Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging HigherAug 19Consensus revenue estimates increase by 62% Aug 19Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint Aug 14Price target decreased by 12% to US$17.25 Aug 08Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price JumpJul 24Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In GrowthJul 12Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy At Retina Meetings in JuneJun 08First quarter 2024 earnings: EPS and revenues miss analyst expectations May 12Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A CatchMay 02Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024May 01Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration studyApr 11Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still UnlikelyMar 15Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 10Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial OfficerFeb 15+ 1 more updateOcuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic RetinopathyFeb 06Ocuphire Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.Jan 11+ 1 more updateInvestor sentiment improves as stock rises 17% Dec 27Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023Dec 07Insufficient new directors Dec 01Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating OfficerNov 29Consensus revenue estimates increase by 24% Nov 20New minor risk - Shareholder dilution Nov 17Ocuphire Pharma, Inc. Announces Chief Executive Officer ChangesNov 02+ 1 more updateInvestor sentiment deteriorates as stock falls 16% Oct 03Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) AgentsSep 28재무 상태 분석단기부채: IRD 의 단기 자산 ( $50.0M )이 단기 부채( $7.8M ).장기 부채: IRD의 단기 자산($50.0M)이 장기 부채($27.1M)를 초과합니다.부채/자본 비율 추이 및 분석부채 수준: IRD 총 부채보다 더 많은 현금을 보유하고 있습니다.부채 감소: IRD의 부채 대비 자본 비율은 지난 5년 동안 0%에서 7.4%로 증가했습니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: IRD 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.예측 현금 활주로: IRD 17.1 1.2 17.1 % 매년.건전한 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/01 11:56종가2026/05/01 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Opus Genetics, Inc.는 14명의 분석가가 다루고 있습니다. 이 중 15명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관James MolloyAlliance Global PartnersMadison Wynne El-SaadiB. Riley Securities, Inc.Kumaraguru RajaBrookline Capital Markets11명의 분석가 더 보기
Opus Genetics, Inc. announced that it expects to receive $159.928 million in funding from Oberland Capital Management LLCApr 07
Opus Genetics, Inc. Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual MeetingFeb 27
Opus Genetics, Inc. Announces Fda Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaFeb 25
Opus Genetics, Inc. announced that it has received $25.000002 million in funding from Adage Capital Management, L.P., Trails Edge Capital Partners, LP, Marshall Wace LLPFeb 20
Opus Genetics, Inc. announced that it expects to receive $25.000002 million in funding from Adage Capital Management, L.P., Trails Edge Capital Partners, LP, Marshall Wace LLPFeb 14
Opus Genetics, Inc. Launches Gene Therapy Clinical Trial for Mertk-Related Retinitis PigmentosaJan 27
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best DiseaseDec 10
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best DiseaseNov 13
Opus Genetics, Inc. Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal DiseaseNov 08
Opus Genetics, Inc. Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5Oct 02
Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking After Shares Rocket 31%Sep 09
Opus Genetics, Inc. Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast ConditionsSep 05
Opus Genetics Inherited Retinal Disease Programs Featured At Medical and Industry Conferences in SeptemberAug 28
Opus Genetics, Inc. Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaJun 26+ 2 more updates
Opus Genetics, Inc. Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast ConditionsJun 02
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy CandidateMay 07
Opus Genetics Announces One-Year Results from Adult Patients Treated in the Ongoing Phase 1/2 Study of Its Lead Gene Therapy Candidate OPGx-LCA5May 06
Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal DiseasesApr 08
Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.Mar 21+ 1 more update
Opus Genetics, Inc. Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025Mar 06
Opus Genetics, Inc. Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% ProgramsFeb 26
Opus Genetics, Inc. Announces First Pediatric Patient Was Dosed in its Ongoing Phase 1/2 Clinical Trial Evaluating OPGx-LCA5, its Investigational Gene Therapy for the Treatment of Leber Congenital AmaurosisFeb 18
Opus Genetics, Inc. to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024Dec 04
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in OphthalmologyOct 01
Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price JumpJul 24
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy At Retina Meetings in JuneJun 08
Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration studyApr 11
Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still UnlikelyMar 15
Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial OfficerFeb 15+ 1 more update
Ocuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic RetinopathyFeb 06
Ocuphire Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.Jan 11+ 1 more update
Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023Dec 07
Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) AgentsSep 28
